Ray Dalio's RMD Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 32,924 shares of ResMed Inc. (RMD) worth $7.93 M, representing 0.03% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in RMD, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 83,388 shares. Largest reduction occurred in Q2 2025, reducing 114,077 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's ResMed (RMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ResMed (RMD) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +942 | Add 2.95% | 32,924 | $240.87 |
| Q3 2025 | +26,728 | Add 508.72% | 31,982 | $273.73 |
| Q2 2025 | -114,077 | Reduce 95.60% | 5,254 | $258.00 |
| Q1 2025 | +32,060 | Add 36.74% | 119,331 | $223.85 |
| Q4 2024 | -6,626 | Reduce 7.06% | 87,271 | $228.69 |
| Q3 2024 | -72,216 | Reduce 43.47% | 93,897 | $244.12 |
| Q2 2024 | +17,407 | Add 11.71% | 166,113 | $191.42 |
| Q1 2024 | -9,820 | Reduce 6.19% | 148,706 | $198.03 |
| Q4 2023 | -71,997 | Reduce 31.23% | 158,526 | $172.02 |
| Q3 2023 | +58,199 | Add 33.77% | 230,523 | $147.87 |
| Q2 2023 | -20,537 | Reduce 10.65% | 172,324 | $218.50 |
| Q1 2023 | -20,312 | Reduce 9.53% | 192,861 | $218.99 |
| Q4 2022 | -53,593 | Reduce 20.09% | 213,173 | $208.13 |
| Q3 2022 | +23,845 | Add 9.82% | 266,766 | $218.30 |
| Q2 2022 | -27,869 | Reduce 10.29% | 242,921 | $209.63 |
| Q1 2022 | +83,388 | Add 44.50% | 270,790 | $242.51 |
| Q4 2021 | +26,053 | Add 16.15% | 187,402 | $260.48 |
| Q3 2021 | -3,466 | Reduce 2.10% | 161,349 | $263.55 |
| Q2 2021 | +75,028 | Add 83.56% | 164,815 | $246.52 |
| Q1 2021 | +15,508 | Add 20.88% | 89,787 | $194.01 |
| Q4 2020 | +37,854 | Add 103.92% | 74,279 | $212.56 |
| Q3 2020 | +36,425 | New Buy | 36,425 | $171.42 |
| Q2 2020 | -3,371 | Sold Out | 0 | $0.00 |
| Q1 2020 | +3,371 | New Buy | 3,371 | $147.43 |
| Q1 2019 | -8,119 | Sold Out | 0 | $0.00 |
| Q4 2018 | +8,119 | New Buy | 8,119 | $113.93 |
| Q3 2018 | -5,565 | Sold Out | 0 | $0.00 |
| Q2 2018 | -4,067 | Reduce 42.22% | 5,565 | $103.50 |
| Q1 2018 | +9,632 | New Buy | 9,632 | $98.42 |
| Q2 2016 | -49,576 | Sold Out | 0 | $0.00 |
| Q1 2016 | +49,576 | New Buy | 49,576 | $57.81 |
| Q4 2015 | -13,788 | Sold Out | 0 | $0.00 |
| Q3 2015 | +7,800 | Add 130.26% | 13,788 | $50.99 |
| Q2 2015 | +5,988 | New Buy | 5,988 | $56.45 |
Ray Dalio's ResMed Investment FAQs
Ray Dalio first purchased ResMed Inc. (RMD) in Q2 2015, acquiring 5,988 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held ResMed Inc. (RMD) for 34 quarters since Q2 2015.
Ray Dalio's largest addition to ResMed Inc. (RMD) was in Q1 2022, adding 270,790 shares worth $65.67 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 32,924 shares of ResMed Inc. (RMD), valued at approximately $7.93 M.
As of the Q4 2025 filing, ResMed Inc. (RMD) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in ResMed Inc. (RMD) was 270,790 shares, as reported at the end of Q1 2022.